Immunomodulatory Strategies for Huntington's Disease Treatment

Title:Immunomodulatory Strategies for Huntington's Disease Treatment

Volume: 16 Issue: 8

Author(s): Gabriela D. Colpo*, Natalia P. Rocha, Erin Fur Stimming and Antonio L. Teixeira

Affiliation:

• Neuropsychiatry Program, Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX,United States

Keywords: Huntington's disease, inflammation, treatment, symptomatic therapies, disease modifying treatment, stem cells.

Abstract: Background & Objective: Huntington's disease (HD) is an autosomal-dominant, progressive neurodegenerative disease characterized by selective loss of neurons in the striatum and cortex, which leads to progressive motor dysfunction, cognitive decline and behavioral symptoms. HD is caused by a trinucleotide (CAG) repeat expansion in the gene encoding the protein huntingtin. Despite the fact that the HD gene was identified over 20 years ago, there is no effective disease-modifying therapy for HD and only symptomatic therapies are available to date. Recently, new agents and procedures have been investigated for HD and many of them have focused on immunomodulatory and/or anti- inflammatory strategies.

Conclusion: The objective of the current review is to summarize data on the therapeutic strategies to treat HD that are based on immunomodulatory effects.

Cite this article as:

Colpo D. Gabriela *, Rocha P. Natalia , Stimming Fur Erin and Teixeira L. Antonio, Immunomodulatory Strategies for Huntington's Disease Treatment, CNS & Neurological Disorders - Drug Targets 2017; 16(8) . https://dx.doi.org/10.2174/1871527316666170613084801